Skip to main content

An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours Harbouring Alterations in the PI3K/AKT/PTEN Pathway

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca Pharmaceuticals, LP

Start Date

November 19, 2021

End Date

April 17, 2024
 

Administered By

Duke Cancer Institute

Awarded By

AstraZeneca Pharmaceuticals, LP

Start Date

November 19, 2021

End Date

April 17, 2024